NSE ScannerPharmaceuticals · Pharmaceuticals: Other · NSE: CIPLA · data 2026-10-30
Cipla Ltd
In plain words
Price: 10.4% below its 52-week high of ₹1,539.7.
Delivery: 55.8% of traded shares were kept for delivery over the last 10 sessions, against 56.3% over the last 60.
Latest results: a net profit of ₹878 cr for the quarter ended Sept 2026 (-35.1% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹28,139 cr |
| Net profit (last 12 months) | ₹2,897 cr |
| Sales growth, 3 years (yearly) | 7.3% |
| Profit growth, 3 years (yearly) | 11.5% |
Latest results in brief (Q2 FY27)
CIPLA Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹7,403.93 crore, down 2.4% YoY and up 4% QoQ.
Net profit was ₹877.54 crore, down 35.1% YoY and up 11.2% QoQ.
Operating margin was 18.7% (25% a year ago).
EPS was ₹10.86, down 35.1% YoY and up 11.2% QoQ.
CIPLA के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹7,403.93 करोड़; पिछले साल की तुलना में 2.4% की गिरावट, पिछली तिमाही की तुलना में 4% की बढ़त।
शुद्ध मुनाफ़ा: ₹877.54 करोड़; पिछले साल की तुलना में 35.1% की गिरावट, पिछली तिमाही की तुलना में 11.2% की बढ़त।
ऑपरेटिंग मार्जिन: 18.7% (एक साल पहले 25%)।
EPS: ₹10.86; पिछले साल की तुलना में 35.1% की गिरावट, पिछली तिमाही की तुलना में 11.2% की बढ़त।
CIPLAના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹7,403.93 કરોડ; ગયા વર્ષની સરખામણીએ 2.4% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 4% વધારો.
ચોખ્ખો નફો: ₹877.54 કરોડ; ગયા વર્ષની સરખામણીએ 35.1% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 11.2% વધારો.
ઓપરેટિંગ માર્જિન: 18.7% (એક વર્ષ પહેલાં 25%).
EPS: ₹10.86; ગયા વર્ષની સરખામણીએ 35.1% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 11.2% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
27/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 6/30: Delivery 54.9% over the last 20 sessions vs 55.8% in the 40 before (0.98x); shares delivered per day 1.28x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 15/15: 52 schemes hold it, about ₹8,224 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 1/15: Verdict "None", sustained score 30/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 27 Oct 26Results Q2 FY27 results: profit −35.1% YoY +0.8% next session
- 23 Jul 26Results Q1 FY27 results: profit −39.2% YoY -0.3% next session
- 5 Jun 26Dividend Dividend ₹13 (ex-date) -0.8% next session
- 13 May 26Results Q4 FY26 results: profit −54.6% YoY +11.2% next session
- 23 Jan 26Results Q3 FY26 results: profit −57.0% YoY -4.2% next session
- 30 Oct 25Results Q2 FY26 results: profit +3.7% YoY -5.0% next session
- 25 Jul 25Results Q1 FY26 results: profit +10.2% YoY +5.7% next session
- 27 Jun 25Dividend Dividend ₹13 (ex-date) -0.5% next session
- 13 May 25Results Q4 FY25 results: profit +30.1% YoY -1.1% next session
- 29 Jan 25Results Q3 FY25 results: profit +48.7% YoY +2.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹7,404 cr | ₹878 cr | -35.1% | 18.7% | 10.86 |
| Jun 2026 | ₹7,119 cr | ₹789 cr | -39.2% | 16.7% | 9.77 |
| Mar 2026 | ₹6,541 cr | ₹555 cr | -54.6% | 14.6% | 6.87 |
| Dec 2025 | ₹7,074 cr | ₹676 cr | -57.0% | 17.7% | 8.37 |
Common questions
What was Cipla Ltd's latest quarterly profit?
Cipla Ltd reported a net profit of ₹878 cr for the quarter ended Sept 2026 (-35.1% on the same quarter a year earlier), on revenue of ₹7,404 cr.
Is Cipla Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.02, which is very low.
What is Cipla Ltd's P/E ratio?
About 38.5, based on the last 12 months' earnings and a price of ₹1,378.9 (data 2026-10-30).
What is the 52-week high and low of Cipla Ltd?
The 52-week high is ₹1,539.7 and the 52-week low is ₹1,165.7.
Mutual funds holding Cipla Ltd
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 52 schemes holding about ₹8,224 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Parag Parikh Flexi Cap Fund | PPFAS Mutual Fund | 1.33% | ₹1,929 cr |
| SBI Nifty 50 ETF | SBI Mutual Fund | 0.72% | ₹1,462 cr |
| SBI ELSS Tax Saver Fund | SBI Mutual Fund | 2.13% | ₹640 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 6.01% | ₹551 cr |
| NIPPON INDIA LARGE CAP FUND | Nippon India Mutual Fund | 1.07% | ₹549 cr |
| SBI Contra Fund | SBI Mutual Fund | 1.15% | ₹518 cr |
| NIPPON INDIA ETF NIFTY 50 BEES | Nippon India Mutual Fund | 0.72% | ₹469 cr |
| Nippon India Multi Cap Fund | Nippon India Mutual Fund | 0.64% | ₹344 cr |
| SBI Balanced Advantage Fund | SBI Mutual Fund | 0.71% | ₹288 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 4.40% | ₹258 cr |
| ADITYA BIRLA SUN LIFE FLEXI CAP FUND | Aditya Birla Sun Life Mutual Fund | 0.68% | ₹190 cr |
| SBI MNC Fund | SBI Mutual Fund | 2.11% | ₹135 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 7.68% | ₹133 cr |
| SBI Large Cap Fund | SBI Mutual Fund | 0.19% | ₹100 cr |
| SBI Nifty Index Fund | SBI Mutual Fund | 0.73% | ₹96 cr |
Similar companies
Aurobindo Pharma Ltd (AUROPHARMA) · Lupin Limited (LUPIN) · Granules India Limited (GRANULES) · Sudeep Pharma Limited (SUDEEPPHRM) · Amrutanjan Health Care Limited (AMRUTANJAN)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open CIPLA in NSE Scanner →